Xenon and Therapeutical Hypothermia After Successful CardiopulmonaryResuscitatio

Conditions: In this clinical trial will be checked, whether 2 hours ventilation with xenon has neuroprotetctive effect on the patients, which had out of hospital cardiac arrest and successful cardiopulmonary resuscitation
MedDRA version: 16.1Level: PTClassification code 10067221Term: Mechanical ventilationSystem Organ Class: 10042613 - Surgical and medical procedures
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Registration Number: EUCTR2010-022679-71-DE

Lead Sponsor: Clinical Trials Center Aachen, University of Aachen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Patients with out of hospital cardiac arrest and successeful cardiopulmonary resuscitation, which will be treated with therapeutic hypothermia at Department of Internal Medicine I of Teaching Hospital of Unversity of Aachen
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

- Patients younger than 18 years
- Xenon allergy
- Pregnancy
- High inspired oxygen requirement (> 70%) in order to maintain adequate arterial
oxygen saturation (SpO2> 94%) at the beginning of treatment

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Feasibility and safety of combined treatment of xenon and therapeutic hypothermia in patients with successfull cardiopulmonary resuscitation after out of hospital cardiac arrest ;Secondary Objective: Influence of combined treatment of xenon and therapeutic hypothermia on neurological outcome , cardiac function and mortality in patients with successfull cardiopulmonary resuscitation after out of hospital cardiac arrest ;Primary end point(s): Safety and efficacy of xenon ventilation within 2 hours after successful cardiopulmonale resuscitation;Timepoint(s) of evaluation of this end point: during 2h of Xenon-Ventilation

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): Significant difference between treatment group and control group.;Timepoint(s) of evaluation of this end point: within 28 days after cardiac arrest